Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Feb 26, 2016 at 12:25 PM EST

Why Peregrine Absolutely Tanked

Peregine Pharmaceuticals has announced that it is discontinuing its Phase 3 Sunrise trial of bavituximab in patients with previously treated…

Trey Thoelcke | Feb 26, 2016 at 11:56 AM EST

Big Pharma Matchup: Valeant vs Gilead

Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion…

Jon C. Ogg | Feb 25, 2016 at 5:15 PM EST

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four…

Chris Lange | Feb 25, 2016 at 8:46 AM EST

Short Interest Rises Across the Board in Major Biotechs

The February 12 short interest data have been compared with the previous report, and short interest increased across the board…

Chris Lange | Feb 25, 2016 at 8:10 AM EST

Short Sellers Increase Bets in Major Pharma

The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | Feb 24, 2016 at 12:45 PM EST

Pfizer Sinks Despite Winning FDA Approval

Pfizer has announced that the FDA approved Xeljanz XR (tofacitinib citrate) extended-release tablets for the once-daily treatment of moderate to…

Chris Lange | Feb 23, 2016 at 9:55 AM EST

PTC Therapeutics Craters on FDA Letter

PTC Therapeutics said that it has received a Refuse to File letter from the FDA regarding its New Drug Application…

Lee Jackson | Feb 22, 2016 at 11:40 AM EST

Big Dividend Pharmaceutical Stock Now Jefferies Top Global Sector Pick

In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend…

Chris Lange | Feb 22, 2016 at 10:05 AM EST

Trevena Jumps on Breakthrough Therapy Designation

Trevena charged after the FDA granted a Breakthrough Therapy designation to its lead product candidate for the management of acute…

Chris Lange | Feb 22, 2016 at 9:55 AM EST

How Allergan Beat Q4 Earnings Estimates

Allergan reported better-than-expected fourth-quarter financial results before the markets opened on Monday.

Chris Lange | Feb 22, 2016 at 9:45 AM EST

Chimerix Stumbles Over Late Stage Results

Chimerix had a bad start to the week as it tumbled in early trading on Monday, following some late stage…

Chris Lange | Feb 20, 2016 at 10:15 AM EST

The Top 4 Biopharma Movers of the Past Week

Over the past week, Zafgen and a few other biotech companies made impressive runs. These moves were the result of…

Trey Thoelcke | Feb 19, 2016 at 7:10 AM EST

AstraZeneca Gets European Approval for Heart Attack, Gout Treatments

AstraZeneca has announced that the European Commission granted marketing authorization for two of its treatments: Zurampic for gout and Brilique…

Chris Lange | Feb 18, 2016 at 10:05 AM EST

Exagen Updates IPO Filing

Exagen Diagnostics has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Chris Lange | Feb 18, 2016 at 9:55 AM EST

Aerie Pharma Jumps on Positive Interim Safety Results

Aerie Pharmaceuticals was one of the more bullish health care stocks on Thursday morning, following the release of its interim…

1 … 221 222 223 224 225 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Peregrine Absolutely Tanked

Big Pharma Matchup: Valeant vs Gilead

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Short Sellers Increase Bets in Major Pharma

Pfizer Sinks Despite Winning FDA Approval

PTC Therapeutics Craters on FDA Letter

Big Dividend Pharmaceutical Stock Now Jefferies Top Global Sector Pick

Trevena Jumps on Breakthrough Therapy Designation

How Allergan Beat Q4 Earnings Estimates

Chimerix Stumbles Over Late Stage Results

The Top 4 Biopharma Movers of the Past Week

AstraZeneca Gets European Approval for Heart Attack, Gout Treatments

Exagen Updates IPO Filing

Aerie Pharma Jumps on Positive Interim Safety Results

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Tesla vs Ford: One Is a Disrupter While One Is Quietly Building Legacy

These 4 Dividend Growers Have Already Declared 10% Dividend Increases

Analysts See 118% Upside for Strategy After Bitcoin Crashed 27% in 6 Months

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income

Seven Out of Every Ten Dollars of Americans $18.8 Trillion Debt Is Tied To A House

Tesla vs Ford: One Is a Disrupter While One Is Quietly Building Legacy

These 4 Dividend Growers Have Already Declared 10% Dividend Increases

Health and Healthcare Articles

All Health and Healthcare Articles

Why Peregrine Absolutely Tanked

Big Pharma Matchup: Valeant vs Gilead

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Short Sellers Increase Bets in Major Pharma

Pfizer Sinks Despite Winning FDA Approval

PTC Therapeutics Craters on FDA Letter

Big Dividend Pharmaceutical Stock Now Jefferies Top Global Sector Pick

Trevena Jumps on Breakthrough Therapy Designation

How Allergan Beat Q4 Earnings Estimates

Chimerix Stumbles Over Late Stage Results

The Top 4 Biopharma Movers of the Past Week

AstraZeneca Gets European Approval for Heart Attack, Gout Treatments

Exagen Updates IPO Filing

Aerie Pharma Jumps on Positive Interim Safety Results

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Tesla vs Ford: One Is a Disrupter While One Is Quietly Building Legacy

These 4 Dividend Growers Have Already Declared 10% Dividend Increases

Analysts See 118% Upside for Strategy After Bitcoin Crashed 27% in 6 Months

Featured Reads

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income

Seven Out of Every Ten Dollars of Americans $18.8 Trillion Debt Is Tied To A House